Eleven Biotherapeutics

Committee Composition
Wendy L. Dixon, Ph.D.

Wendy L. Dixon, Ph.D. has served as a member of our board of directors since October 2014 and as Chairman since December 2016. Dr. Dixon has been the President of Great Meadow Consulting, L.L.C., a life science consulting firm, since July 2009. Additionally, Dr. Dixon has been an advisor to the Mellon Group since August 2014 and was a Senior Advisor to The Monitor Group, now Deloitte Consulting LLP, a consulting firm, from November 2010 to January 2012. Dr. Dixon has also been a member of the Industry Advisory Board of Longitude Capital, a venture capital firm, since March 2015. From 2001 to 2009, Dr. Dixon was the Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb, where she served on the Executive Committee. From 1996 to 2001, she was the Senior Vice President, Marketing at Merck and Co., and prior to that, she held executive management positions at West Pharmaceuticals, Osteotech and Centocor and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon serves on the board of directors of Alkermes plc, Incyte Corporation, bluebird bio, and Orexigen Therapeutics, and was formerly on the boards of Ardea Biosciences, when Ardea was acquired by AstraZeneca plc, Furiex Pharmaceuticals, when Furiex was acquired by Actavis plc, and Dentsply International. Dr. Dixon received a B.S. and a M.S. in Natural Science and a Ph.D. in Biochemistry from the University of Cambridge (UK).


Abbie Celniker, Ph.D.

Abbie C. Celniker, Ph.D. has served as a member of our board of directors since September 2011 and as President and Chief Executive Officer of Eleven Biotherapeutics from 2011 to 2016. Prior to joining Eleven Biotherapeutics, Dr. Celniker served as the Executive Vice President, Translational Medicine of Alexion Pharmaceuticals, Inc., a biopharmaceutical company, from January 2011 to August 2011. Prior to joining Alexion Pharmaceuticals, Dr. Celniker served as the President and Chief Executive Officer and as a member of the board of directors of Taligen Therapeutics, Inc., a biotechnology company, from July 2008 to January 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals. Previously, Dr. Celniker served as the Global Head of Biologics of Novartis AG, the Senior Vice President of Research and Development Strategy and Operations of Millennium Pharmaceuticals, Inc. and the Vice President Protein Technologies of the Wyeth Research facilities in Cambridge, Massachusetts. Dr. Celniker is the Chair of the MassBio board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. Dr. Celniker is also a member of the board of directors of the nonprofit Unitio and T1D has a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of Arizona.


Paul Chaney

Paul Chaney has served as a member of our board of directors since February 2014. Mr. Chaney is a co-founder of PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmic therapeutics and has served as its President and Chief Executive Officer since 2009. Prior to co-founding PanOptica, Mr. Chaney was executive vice president of OSI Pharmaceuticals, Inc. and president of (OSI) Eyetech, Inc., OSI Pharmaceutical's wholly-owned eyecare subsidiary. Mr. Chaney joined Eyetech Pharmaceuticals as Chief Operating Officer in 2003. Prior to joining Eyetech, Mr. Chaney held a variety of senior management positions at Pharmacia Corporation, including Vice President of the Global Ophthalmology Business and Vice President of Global Pharmaceutical Ophthalmology. Mr. Chaney also serves as the chairman of the board of directors of Eyegate Pharmaceuticals, Inc.  He began his career as a sales representative for The Upjohn Company in 1980. Mr. Chaney earned a dual degree in Biological Sciences and English from the University of Delaware. 


Leslie L. Dan, B.Sc. Phm., M.B.A., C.M.

Leslie L. Dan, B.Sc. Phm., M.B.A., C.M., is the founder of Viventia Bio, Inc. He was appointed the chair of Viventia’s board of directors in January 2013 and served as the company’s president and secretary from 2012 to 2015. Mr. Dan also founded Novopharm (now known as Teva Canada Limited) in 1964, now a wholly-owned subsidiary of Teva Pharmaceuticals Industries Limited, and has served on Teva Canada’s board of directors as chairman since 2000. Mr. Dan also served on the board of directors of Draxis Health Inc. (now known as Draxis Specialty Pharmaceuticals Inc.), a provider of sterile products, non-sterile products and radiopharmaceuticals, from 1993 to 2003, and on the board of directors of Teva Israel from 2001 to 2007. Mr. Dan graduated from the University of Toronto with a B.Sc. Phm. in 1954 and an M.B.A. in 1959. He has also received honorary doctorates from the University of British Columbia, Dalhousie University, York University and the University of Toronto.


Jay S. Duker, M.D.

Jay S. Duker, M.D., has served as a member of our board of directors since January 2015. Dr. Duker has served in varying capacities at the New England Eye Center (NEEC) since January 1992, most recently as Director since 2001. He has also served as Professor and Chairman of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine since 2003. He has published more than 185 journal articles, with his major research interests including retinal imaging, in particular optical coherence tomography (OCT), retinal vascular diseases, and drug delivery to the posterior segment. His book, Yanoff and Duker's Ophthalmology, is one of the bestselling ophthalmic texts over the past decade. Dr. Duker is the co-founder of three companies including Hemera Biosciences, a biotech start-up whose focus is a gene therapy based treatment for age-related macular degeneration. Dr. Duker received an A.B. from Harvard University and a M.D. from the Jefferson Medical College at Thomas Jefferson University.


Barry J. Gertz, M.D., Ph.D.

Barry J. Gertz, M.D, Ph.D. has served as a member of our board of directors since January 2015. Since October 2014, Dr. Gertz has served as a venture partner at Clarus Ventures, a venture capital firm. Prior to his time with Clarus Ventures, Dr. Gertz served in varying roles at Merck & Co., Inc., a pharmaceutical company, from 1986 until July 2014, including as Senior Vice President from 2002 to 2014. Dr. Gertz has co-authored over 100 scientific publications and has been a contributor to the evaluation and approval of more than 25 new drugs or vaccines. Dr. Gertz received a B.A. in chemistry from the University of Pennsylvania. He subsequently received M.D. and Ph.D. degrees in the Medical Scientist Training Program at the University of Pennsylvania, School of Medicine with a Ph.D. in the Department of Pharmacology.


Jane V. Henderson

Jane Henderson has served as a member of our board of directors since October 2013. In 2017 Ms. Henderson joined Voyager Therapeutics as Senior Vice President and Chief Financial Officer. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., having joined the privately-held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc., in late 2016. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., from June 2010 to June 2012, when ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson also served as the Chief Financial Officer and Head of Business Development at Axerion Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms. Henderson's extensive healthcare investment banking experience includes the execution of over 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University.


Stephen Hurly

Stephen A. Hurly brings nearly two decades of leadership experience in the life sciences industry. Prior to his role as president and CEO of Eleven, he joined Viventia as chief executive officer in March 2014. Previously, Mr. Hurly was the chief executive officer of Burrill & Co.’s Merchant Banking Division, a finance business for life science companies, from 2011 to 2014. Prior to that, Mr. Hurly was the head of the Life Sciences Investment Banking Practice at Boenning & Scattergood, a securities asset management and investment banking firm, from 2008 to 2011. Mr. Hurly has more than 15 years of experience in the investment banking business. Mr. Hurly currently serves on the board of directors of PHusis Therapeutics Inc., a targeted small molecule therapeutics company, since May 2011. He graduated from Swarthmore College with a B.A. degree in Engineering in 1990 and earned an M.B.A. from the University of Chicago in 1997.


Daniel S. Lynch

Daniel S. Lynch served as the Chairman of our board of directors from 2013-2016. Mr. Lynch has served as a venture partner at Third Rock Ventures, a venture capital firm, since May 2013 and as an entrepreneur-in residence from May 2011 to May 2013. Since 2005, Mr. Lynch has served on the boards of directors of several life sciences companies, including on the board of directors of BIND Therapeutics, Inc. since 2012, on the board of directors of bluebird bio, Inc. since 2011, and as executive chairman of the board of directors for Blueprint Medicines Corp. since 2012. Prior to that, Mr. Lynch served as the Chief Financial Officer and then the Chief Executive Officer of ImClone Systems Inc. Mr. Lynch received a B.A. in Mathematics from Wesleyan University and a M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia. 


  Audit Nominating and Governance Compensation
Wendy L. Dixon, Ph.D. Chairman of the Board
X Image of Wendy L. Dixon, Ph.D.
Wendy L. Dixon, Ph.D.
Chairman of the Board of Directors

Wendy L. Dixon, Ph.D. has served as a member of our board of directors since October 2014 and as Chairman since December 2016. Dr. Dixon has been the President of Great Meadow Consulting, L.L.C., a life science consulting firm, since July 2009. Additionally, Dr. Dixon has been an advisor to the Mellon Group since August 2014 and was a Senior Advisor to The Monitor Group, now Deloitte Consulting LLP, a consulting firm, from November 2010 to January 2012. Dr. Dixon has also been a member of the Industry Advisory Board of Longitude Capital, a venture capital firm, since March 2015. From 2001 to 2009, Dr. Dixon was the Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb, where she served on the Executive Committee. From 1996 to 2001, she was the Senior Vice President, Marketing at Merck and Co., and prior to that, she held executive management positions at West Pharmaceuticals, Osteotech and Centocor and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon serves on the board of directors of Alkermes plc, Incyte Corporation, bluebird bio, and Orexigen Therapeutics, and was formerly on the boards of Ardea Biosciences, when Ardea was acquired by AstraZeneca plc, Furiex Pharmaceuticals, when Furiex was acquired by Actavis plc, and Dentsply International. Dr. Dixon received a B.S. and a M.S. in Natural Science and a Ph.D. in Biochemistry from the University of Cambridge (UK).

Member of Audit Committee   Member of Compensation Committee
Paul Chaney
X Image of Paul Chaney
Paul Chaney
Director

Paul Chaney has served as a member of our board of directors since February 2014. Mr. Chaney is a co-founder of PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmic therapeutics and has served as its President and Chief Executive Officer since 2009. Prior to co-founding PanOptica, Mr. Chaney was executive vice president of OSI Pharmaceuticals, Inc. and president of (OSI) Eyetech, Inc., OSI Pharmaceutical's wholly-owned eyecare subsidiary. Mr. Chaney joined Eyetech Pharmaceuticals as Chief Operating Officer in 2003. Prior to joining Eyetech, Mr. Chaney held a variety of senior management positions at Pharmacia Corporation, including Vice President of the Global Ophthalmology Business and Vice President of Global Pharmaceutical Ophthalmology. Mr. Chaney also serves as the chairman of the board of directors of Eyegate Pharmaceuticals, Inc.  He began his career as a sales representative for The Upjohn Company in 1980. Mr. Chaney earned a dual degree in Biological Sciences and English from the University of Delaware. 

    Member of Compensation Committee
Jane V. Henderson
X Image of Jane V. Henderson
Jane V. Henderson
Director

Jane Henderson has served as a member of our board of directors since October 2013. In 2017 Ms. Henderson joined Voyager Therapeutics as Senior Vice President and Chief Financial Officer. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., having joined the privately-held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc., in late 2016. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., from June 2010 to June 2012, when ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson also served as the Chief Financial Officer and Head of Business Development at Axerion Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms. Henderson's extensive healthcare investment banking experience includes the execution of over 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University.

Committee Chair for Audit Committee Member of Nominating and Governance Committee  
Daniel S. Lynch
X Image of Daniel S. Lynch
Daniel S. Lynch
Director

Daniel S. Lynch served as the Chairman of our board of directors from 2013-2016. Mr. Lynch has served as a venture partner at Third Rock Ventures, a venture capital firm, since May 2013 and as an entrepreneur-in residence from May 2011 to May 2013. Since 2005, Mr. Lynch has served on the boards of directors of several life sciences companies, including on the board of directors of BIND Therapeutics, Inc. since 2012, on the board of directors of bluebird bio, Inc. since 2011, and as executive chairman of the board of directors for Blueprint Medicines Corp. since 2012. Prior to that, Mr. Lynch served as the Chief Financial Officer and then the Chief Executive Officer of ImClone Systems Inc. Mr. Lynch received a B.A. in Mathematics from Wesleyan University and a M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia. 

Member of Audit Committee Committee Chair for Nominating and Governance Committee Committee Chair for Compensation Committee
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member
NASDAQ: EBIO
Price:
1.58
Change:
- 0.03
Day High:
1.67
Day Low:
1.54
Volume:
241,894
12:05 PM ET on September 20, 2017
Delayed at least 20 minutes.